110,507 results match your criteria Ovarian Cancer


Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis.

Mol Biol Rep 2019 Apr 20. Epub 2019 Apr 20.

School of Life and Environmental Sciences, University of Sydney, Sydney, Australia.

Ovarian cancer (OC) is the fourth most common cancer among Pakistani, Scottish and Chinese women. The aim of the present study was to determine the association of potential risk factors with OC and analysis of Cancer Antigen 125 (CA125) in its monitoring and diagnosis. A total of 200 patients diagnosed with OC were included in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11033-019-04794-8DOI Listing

Management of postoperative chylous ascites after surgery for ovarian cancer: a single-institution experience.

Updates Surg 2019 Apr 20. Epub 2019 Apr 20.

Division of Gynecologic Oncology, Department of Women's and Children's Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Postoperative chylous ascites is a rare complication from operative trauma to the cisterna chyli or lymphatic vessels in the retroperitoneum. In the present study, we aimed to identify the incidence of postoperative chylous ascites in patients treated for ovarian cancer and to describe its management. We retrospectively reviewed all patients submitted to surgery for ovarian cancer at our Institution from October 2016 to November 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13304-019-00656-xDOI Listing

Impact of Implementing B-RST to Screen for Hereditary Breast and Ovarian Cancer on Risk Perception and Genetic Counseling Uptake Among Women in an Academic Safety Net Hospital.

Clin Breast Cancer 2019 Mar 11. Epub 2019 Mar 11.

Department of Human Genetics, Emory University School of Medicine, Atlanta, GA; Winship Cancer Institute of Emory University, Atlanta, GA.

Background: Lower socioeconomic status is strongly associated with decreased perception of cancer risk. Fewer low socioeconomic status women than expected currently access cancer genetic services from which they may benefit.

Patients And Methods: We screened women presenting for a screening mammogram at a safety net academic hospital using the Breast Cancer Genetics Referral Screening Tool Version 3. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15268209183073
Publisher Site
http://dx.doi.org/10.1016/j.clbc.2019.02.014DOI Listing
March 2019
1 Read

An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.

Gynecol Oncol 2019 Apr 17. Epub 2019 Apr 17.

The University of Texas MD Anderson Cancer Centre, Houston, TX, USA.

Objectives: We evaluated four different treatment regimens for advanced-stage mucinous epithelial ovarian cancer.

Methods: We conducted a multicenter randomized factorial trial (UK and US). Patients were diagnosed with primary mEOC: FIGO stage II-IV or recurrence after stage I disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.256DOI Listing

MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients.

Eur J Radiol 2019 May 15;114:146-151. Epub 2019 Mar 15.

Department of Radiology, The Netherlands Cancer Institute, PO Box 900203, 1006 BE, Amsterdam, the Netherlands. Electronic address:

Objectives: To determine the diagnostic performance of MRI with diffusion-weighted imaging (DW-MRI) in assessing the peritoneal tumor load and predicting whether a complete cytoreduction can be achieved in patients with epithelial ovarian cancer (EOC).

Methods: For this observational prospective study, 25 patients with epithelial ovarian cancer scheduled for cytoreductive surgery were included. Patients underwent a 3 T DW-MRI scan prior to surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2019.03.007DOI Listing

Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients.

Psychoneuroendocrinology 2019 Apr 6;106:244-251. Epub 2019 Apr 6.

Diabetes Research Institute, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Miller School of Medicine, University of Miami, United States.

Background: Prior research demonstrates a protective role for oxytocin in ovarian cancer based on its anti-proliferative, anti-migratory, and anti-invasive effects in vitro and in vivo. However, the role of endogenous oxytocin has not been examined in ovarian cancer patients. Oxytocin also has anti-inflammatory properties that have not been examined in cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.psyneuen.2019.04.007DOI Listing
April 2019
1 Read

Establishing reproductive potential and advances in fertility preservation techniques for XY individuals with DSD (differences in sex development).

Clin Endocrinol (Oxf) 2019 Apr 20. Epub 2019 Apr 20.

Elizabeth Garrett Anderson UCL Institute of Women's Health, University College London Hospitals, 250 Euston Road, London, NW12PG.

Discordance between gonadal type and gender identity has often led to an assumption of infertility in patients with differences in sex development (DSD). However, there is now greater recognition of fertility being an important issue for this group of patients. Currently, gonadal tissue that may have fertility potential is not being stored for individuals with DSD and, where gonadectomy forms part of management, is often discarded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cen.13994DOI Listing

The role of inflammation, oxidative stress, angiogenesis, and apoptosis in the pathophysiology of endometriosis: Basic science and new insights based on gene expression.

J Cell Physiol 2019 Apr 19. Epub 2019 Apr 19.

Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.

Endometriosis is a frequent and chronic illness in young women which could be defined by the existence of endometrial stroma and glands outside of the normal site of the lining of the uterus. It has painful symptoms. The advanced stage of endometriosis may lead to gynecological malignancies, such as ovarian cancer, and other complications, including infertility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.28666DOI Listing

Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts.

Sci Rep 2019 Apr 19;9(1):6314. Epub 2019 Apr 19.

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA.

As patient derived xenograft (PDX) models are increasingly used for preclinical drug development, strategies to account for the nonhuman component of PDX RNA expression data are critical to its interpretation. A bioinformatics pipeline to separate donor tumor and mouse stroma transcriptome profiles was devised and tested. To examine the molecular fidelity of PDX versus donor tumors, we compared mRNA differences between paired PDX-donor tumors from nine ovarian cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-42680-2DOI Listing

SMURF1-mediated ubiquitination of ARHGAP26 promotes ovarian cancer cell invasion and migration.

Exp Mol Med 2019 Apr 19;51(4):46. Epub 2019 Apr 19.

Department of Obstetrics and Gynecology, Bao'an Maternity and Child Health Hospital, Jinan University, Shenzhen, 518100, China.

Rho GTPase-activating protein 26 (ARHGAP26) is a negative regulator of the Rho family that converts the small GTP-binding protein RhoA (GTP-RhoA) to its inactive GDP-bound form and is a putative tumor suppressor gene associated with cell growth and migration. Here, the involvement of ARHGAP26 in ovarian cancer cell proliferation and migration was investigated. In this study, low ARHGAP26 expression was observed in ovarian cancer tissues and was associated with a poor overall survival and higher β-catenin expression in patients with ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s12276-019-0236-0
Publisher Site
http://dx.doi.org/10.1038/s12276-019-0236-0DOI Listing
April 2019
1 Read
3.446 Impact Factor

Exposure to aristolochic acid I compromises the maturational competency of porcine oocytes via oxidative stress-induced DNA damage.

Aging (Albany NY) 2019 Apr 19. Epub 2019 Apr 19.

College of Animal Science and Technology, Nanjing Agricultural University, Nanjing 210095, China.

Aristolochic acid (AA) is a class of carcinogenic and nephrotoxic nitrophenanthrene carboxylic acids naturally found in Aristolochia plants. These plants have been widely used as herbal medicines and also enter the human food chain as the persistent soil pollutants. It has been known that AA exposure is implicated in multiple cancer types, kidney failure and ovarian dysfunction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/aging.101911DOI Listing

Immunotherapy of gynecological cancers.

Best Pract Res Clin Obstet Gynaecol 2019 Mar 21. Epub 2019 Mar 21.

Division of Gynecologic Oncology, Segal Cancer Center, Lady Davis Institute of Research, Jewish General Hospital, McGill University, Montreal, Canada. Electronic address:

Oncology treatments have evolved from intuitive, via empiric, to the present precision medicine, with the integration of molecular targeted therapies in our treatment arsenal. The use of the patients' powerful immune system has long been contemplated and recently led to the integration of immunotherapy to overturn the well-documented inhibitory effects of the tumor on the immune system and restore it to a state of activity against the cancer. Recent favorable results have shown the value and effectiveness of immunotherapy against gynecological cancers. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216934193003
Publisher Site
http://dx.doi.org/10.1016/j.bpobgyn.2019.03.005DOI Listing
March 2019
1 Read

REC114 Partner ANKRD31 Controls Number, Timing, and Location of Meiotic DNA Breaks.

Mol Cell 2019 Apr 11. Epub 2019 Apr 11.

Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, USA. Electronic address:

Double-strand breaks (DSBs) initiate the homologous recombination that is crucial for meiotic chromosome pairing and segregation. Here, we unveil mouse ANKRD31 as a lynchpin governing multiple aspects of DSB formation. Spermatocytes lacking ANKRD31 have altered DSB locations and fail to target DSBs to the pseudoautosomal regions (PARs) of sex chromosomes. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10972765193022
Publisher Site
http://dx.doi.org/10.1016/j.molcel.2019.03.023DOI Listing
April 2019
1 Read

Innervation of cervical carcinoma is mediated by cancer-derived exosomes.

Gynecol Oncol 2019 Apr 16. Epub 2019 Apr 16.

Sanford Research, Cancer Biology and Immunotherapy Group, 2301 East 60th St north, Sioux Falls, SD 57104, USA. Electronic address:

Objective: Recently, our laboratory identified sensory innervation within head and neck squamous cell carcinomas (HNSCCs) and subsequently defined a mechanism whereby HNSCCs promote their own innervation via the release of exosomes that stimulate neurite outgrowth. Interestingly, we noted that exosomes from human papillomavirus (HPV)-positive cell lines were more effective at promoting neurite outgrowth than those from HPV-negative cell lines. As nearly all cervical tumors are HPV-positive, we hypothesized that these findings would extend to cervical cancer. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193114
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.04.651DOI Listing
April 2019
1 Read

Trastuzumab-Modified Gold Nanoparticles Labeled with At as a Prospective Tool for Local Treatment of HER2-Positive Breast Cancer.

Nanomaterials (Basel) 2019 Apr 18;9(4). Epub 2019 Apr 18.

Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.

Highly localized radiotherapy with radionuclides is a commonly used treatment modality for patients with unresectable solid tumors. Herein, we propose a novel α-nanobrachytherapy approach for selective therapy of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This uses local intratumoral injection of 5-nm-diameter gold nanoparticles (AuNPs) labeled with an α-emitter (At), modified with polyethylene glycol (PEG) chains and attached to HER2-specific monoclonal antibody (trastuzumab). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/nano9040632DOI Listing

DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1.

Cancers (Basel) 2019 Apr 18;11(4). Epub 2019 Apr 18.

Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Autophagy can protect cancer cells from acute starvation and enhance resistance to chemotherapy. Previously, we reported that autophagy plays a critical role in the survival of dormant, drug resistant ovarian cancer cells using human xenograft models and correlated the up-regulation of autophagy and DIRAS3 expression in clinical samples obtained during "second look" operations. DIRAS3 is an imprinted tumor suppressor gene that encodes a 26 kD GTPase with homology to RAS that inhibits cancer cell proliferation and motility. Read More

View Article

Download full-text PDF

Source
https://www.mdpi.com/2072-6694/11/4/557
Publisher Site
http://dx.doi.org/10.3390/cancers11040557DOI Listing
April 2019
1 Read

Cisplatin: The first metal based anticancer drug.

Authors:
Sumit Ghosh

Bioorg Chem 2019 Apr 11;88:102925. Epub 2019 Apr 11.

Department of Chemistry, Indian Institute of Technology Kanpur, Kanpur, Uttar Pradesh 208016, India. Electronic address:

Cisplatin or (SP-4-2)-diamminedichloridoplatinum(II) is one of the most potential and widely used drugs for the treatment of various solid cancers such as testicular, ovarian, head and neck, bladder, lung, cervical cancer, melanoma, lymphomas and several others. Cisplatin exerts anticancer activity via multiple mechanisms but its most acceptable mechanism involves generation of DNA lesions by interacting with purine bases on DNA followed by activation of several signal transduction pathways which finally lead to apoptosis. However, side effects and drug resistance are the two inherent challenges of cisplatin which limit its application and effectiveness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bioorg.2019.102925DOI Listing
April 2019
2 Reads

Early stage detection and screening of ovarian cancer: A research opportunity and significant challenge for biosensor technology.

Biosens Bioelectron 2019 Mar 20;135:71-81. Epub 2019 Mar 20.

Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario, Canada M5S 3H6. Electronic address:

Women diagnosed with late-stage ovarian cancer suffer a very high rate of mortality. Accordingly, it is imperative to detect and diagnose the disease as early as possible in its development. Achievement of this aim implies relatively large scale screening of women at an age of clinically significance through assay of biomarkers for disease present in blood or serum. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09565663193024
Publisher Site
http://dx.doi.org/10.1016/j.bios.2019.03.041DOI Listing
March 2019
1 Read

Detection of cell-free, exosomal and whole blood mitochondrial DNA copy number in plasma or whole blood of patients with serous epithelial ovarian cancer.

J Biotechnol 2019 Apr 16. Epub 2019 Apr 16.

Department of Human Genetics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Ovarian tumor is one of the leading causes of cancer among women. Patients are diagnosed at an advanced stage, usually. There is a need for new specific and sensitive biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbiotec.2019.04.015DOI Listing

Methyl-Hispolon from Phellinus lonicerinus (Agaricomycetes) Affects Estrogen Signals in MCF-7 Breast Cancer Cells and Premature Aging in Rats.

Int J Med Mushrooms 2019 ;21(4):381-392

Hubei Key Laboratory of Natural Products Research and Development, College of Biological and Pharmaceutical Sciences, China Three Gorges University, Yichang, Hubei, China; Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, Liaoning, China.

We studied Phellinus lonicerinus to determine the cytotoxic effect and the dual estrogenic activities of methyl-hispolon and their relation to estrogen signals in vivo and in vitro. The Glide scores of methyl-hispolon-estrogen receptor α (ERα) and methyl-hispolon-ERβ docked complexes were -7.29 kcal/mol and -6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1615/IntJMedMushrooms.2019030355DOI Listing
January 2019

Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?

J Clin Oncol 2019 Apr 19:JCO1900500. Epub 2019 Apr 19.

1 Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.

A healthy 51-year-old woman presented with increasing abdominal and pelvic pain. Computed tomography imaging of the abdomen and pelvis showed an 11.6-cm pelvic mass, retroperitoneal lymphadenopathy, right hydronephrosis, and mesenteric tumor deposits ( Fig 1A ). Read More

View Article

Download full-text PDF

Source
https://ascopubs.org/doi/10.1200/JCO.19.00500
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00500DOI Listing
April 2019
1 Read

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

J Clin Oncol 2019 Apr 19:JCO1801568. Epub 2019 Apr 19.

1 University of Oklahoma Health Sciences Center, Oklahoma City, OK.

Purpose: To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma.

Methods: Eligible patients were randomly assigned to six cycles of IV paclitaxel 80 mg/m once per week with intravenous (IV) carboplatin area under the curve 6 (IV carboplatin) versus IV paclitaxel 80 mg/m once per week with IP carboplatin area under the curve 6 (IP carboplatin) versus once every 3 weeks IV paclitaxel 135 mg/m over 3 hours day 1, IP cisplatin 75 mg/m day 2, and IP paclitaxel 60 mg/m day 8 (IP cisplatin). All participants received bevacizumab 15 mg/kg IV every 3 weeks in cycles 2 to 22. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01568DOI Listing

Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.

JCO Clin Cancer Inform 2019 Apr(3):1-9

1 Northwestern University, Chicago, IL.

Purpose: Molecular cancer subtyping is an important tool in predicting prognosis and developing novel precision medicine approaches. We developed a novel platform-independent gene expression-based classification system for molecular subtyping of patients with high-grade serous ovarian carcinoma (HGSOC).

Methods: Unprocessed exon array (569 tumor and nine normal) and RNA sequencing (RNA-seq; 376 tumor) HGSOC data sets, with clinical annotations, were downloaded from the Genomic Data Commons portal. Read More

View Article

Download full-text PDF

Source
https://ascopubs.org/doi/10.1200/CCI.18.00096
Publisher Site
http://dx.doi.org/10.1200/CCI.18.00096DOI Listing
April 2019
2 Reads

A 19‑miRNA Support Vector Machine classifier and a 6‑miRNA risk score system designed for ovarian cancer patients.

Oncol Rep 2019 Apr 10. Epub 2019 Apr 10.

Department of Anesthesiology, Beijing Obstetrics and Gynecology Hospital, Dongcheng, Beijing 100001, P.R. China.

Ovarian cancer (OC) is the most common gynecologic malignancy with high incidence and mortality. The present study aimed to develop approaches for determining the recurrence type and identify potential miRNA markers for OC prognosis. The miRNA expression profile of OC (the training set, including 390 samples with recurrence information) was downloaded from The Cancer Genome Atlas database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2019.7108DOI Listing

Dynamic contrast enhanced‑magnetic resonance imaging for the early evaluation of the response to docetaxel in rats with epithelial ovarian cancer.

Oncol Rep 2019 Apr 17. Epub 2019 Apr 17.

Department of Radiology, Zhongshan Hospital, Medical Center of Fudan University, Shanghai 200032, P.R. China.

Dynamic contrast enhanced‑magnetic resonance imaging (DCE‑MRI) contributes to the early detection and prediction of responses to chemotherapy in cancer. The aim of the present study was to investigate the feasibility of quantitative DCE‑MRI parameters for noninvasively predicting the early response to DTX in epithelial ovarian cancer (EOC). In the present study, using 7,12‑dimethylbenz (A) anthracene, orthotopic EOC was induced in Sprague Dawley rats. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/or.2019.7124
Publisher Site
http://dx.doi.org/10.3892/or.2019.7124DOI Listing
April 2019
1 Read

Effects of ginsenoside Rg3 on epigenetic modification in ovarian cancer cells.

Oncol Rep 2019 Apr 12. Epub 2019 Apr 12.

Department of Gynecological Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China.

Epigenetic modifications are closely related to oncogene activation and tumor suppressor gene inactivation. The aim of this study was to determine the effects of ginsenoside Rg3 on epigenetic modification in ovarian cancer cells. Cell proliferation, metastasis, invasion and apoptosis were respectively determined using Cell Counting Kit‑8 (CCK‑8), wound healing, Transwell and flow cytometric assays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2019.7115DOI Listing

1α,25‑Dihydroxyvitamin D3 restrains stem cell‑like properties of ovarian cancer cells by enhancing vitamin D receptor and suppressing CD44.

Oncol Rep 2019 Apr 15. Epub 2019 Apr 15.

Department of Nutrition and Food Hygiene, Soochow University of Public Health, Suzhou, Jiangsu 215123, P.R. China.

Scientific evidence linking vitamin D with various cancer types is growing, but the effects of vitamin D on ovarian cancer stem cell‑like cells (CSCs) are largely unknown. The present study aimed to examine whether vitamin D was able to restrain the stemness of ovarian cancer. A side population (SP) from malignant ovarian surface epithelial cells was identified as CSCs, in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2019.7116DOI Listing

SMYD3 promotes epithelial ovarian cancer metastasis by down-regulating p53 protein stability and promoting p53 ubiquitination.

Carcinogenesis 2019 Apr 19. Epub 2019 Apr 19.

Department of Obstetrics and Gynecology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, China.

Epithelial ovarian cancer (EOC) has a very poor prognosis because of tumor invasiveness. Here, we reported that SMYD3 a lysine methyltransferase was frequently upregulated in EOC and associated with poor prognosis. A series of in vitro assays demonstrated that SMYD3 significantly upgraded the migration ability of EOC cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgz078DOI Listing

Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review.

Cancer Biol Ther 2019 Apr 19:1-7. Epub 2019 Apr 19.

a Department of Pathology , Radboud Institute for Molecular Life Sciences, Radboud university medical center , Nijmegen , The Netherlands.

Acinar cell carcinoma (ACC) is a rare pancreatic neoplasm with dismal prognosis. Insights into the molecular basis of ACC can pave the way for the application of more effective, personalized therapies and detection of patients with hereditary predisposition. Molecular analysis revealed a germline BRCA2 (and CHEK2) mutation in a patient with a rare pancreatic ACC with extensive intraductal growth. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/15384047.2019.1
Publisher Site
http://dx.doi.org/10.1080/15384047.2019.1595274DOI Listing
April 2019
1 Read

Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women.

Cancer Med 2019 Apr 18. Epub 2019 Apr 18.

Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia.

An association between genetic variants in the vitamin D receptor (VDR) gene and epithelial ovarian cancer (EOC) was previously reported in women of African ancestry (AA). We sought to examine associations between genetic variants in VDR and additional genes from vitamin D biosynthesis and pathway targets (EGFR, UGT1A, UGT2A1/2, UGT2B, CYP3A4/5, CYP2R1, CYP27B1, CYP24A1, CYP11A1, and GC). Genotyping was performed using the custom-designed 533,631 SNP Illumina OncoArray with imputation to the 1,000 Genomes Phase 3 v5 reference set in 755 EOC cases, including 537 high-grade serous (HGSOC), and 1,235 controls. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cam4.1996
Publisher Site
http://dx.doi.org/10.1002/cam4.1996DOI Listing
April 2019
1 Read

Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer.

Front Immunol 2019 3;10:691. Epub 2019 Apr 3.

The First Department of Gynecologic Oncology and Gynecology, Medical University of Lublin, Lublin, Poland.

Myeloid-derived suppressor cells (MDSCs) expansion is a hallmark of cancer. Three major MDSC subsets defined as monocytic (M)-MDSCs, polymorphonuclear (PMN)-MDSCs and early stage (e)MDSCs can be revealed in human diseases. However, the clinical relevance and immunosupressive pattern of these cells in epithelial ovarian cancer (EOC) are unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00691DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456713PMC

Coexistence of Papillary Thyroid Cancer and Hashimoto's Thyroiditis Developing within an Ovarian Mature Cystic Teratoma.

J Midlife Health 2019 Jan-Mar;10(1):45-47

Department of Pathology, Recep Tayyip Erdogan University, Medical Faculty, Rize, Turkey.

A wide variety of tissues derived from the three germ layers are seen in ovarian teratomas. Microscopically, the most commonly seen tissues are epidermis, skin adnexa, and neural tissues. Thyroid tissue is present in 10% of ovarian mature cystic teratomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jmh.JMH_48_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459062PMC
April 2019
1 Read

Analysis of Prophylactic Salpingo-oophorectomy at the Time of Hysterectomy for Benign Lesions.

J Midlife Health 2019 Jan-Mar;10(1):29-32

Department of Obstetrics and Gynecology, NKP Salve Institute of Medical Sciences and Research Centre, Nagpur, Maharashtra, India.

Background: Prophylactic salpingo-oophorectomy refers to the removal of clinically normal ovaries at the time of hysterectomy for benign lesions, to reduce the risk of ovarian and breast cancer in future. This risk reduction holds true for high-risk women, i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jmh.JMH_70_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459073PMC

Efficacy of Color Doppler Ultrasonography in Differentiation of Ovarian Masses.

Authors:
Nidhi Sehgal

J Midlife Health 2019 Jan-Mar;10(1):22-28

Department of Radiology, IQ City Narayna Medical College and Hospital, Durgapur, West Bengal, India.

Aim: Early and correct diagnosis of ovarian masses has great impact on the ultimate survival. The present study was done to know the role of color Doppler studies in characterization of ovarian masses and to evaluate its efficacy in diagnosis and differentiation of these neoplasms when used along with grayscale (B-mode) ultrasonography (USG).

Materials And Methods: Over 2 years, in total, 98 patients with adnexal masses were examined, of which only 60 patients who had ovarian masses and were satisfying inclusion criteria were evaluated sonographically. Read More

View Article

Download full-text PDF

Source
http://www.jmidlifehealth.org/text.asp?2019/10/1/22/255277
Publisher Site
http://dx.doi.org/10.4103/jmh.JMH_23_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459069PMC
April 2019
1 Read

Screening for Ovarian Cancer: An Update.

Authors:
Ranu Patni

J Midlife Health 2019 Jan-Mar;10(1):3-5

Director, Division of Gynecologic Oncology, Prayaas Clinic, Jaipur, Rajasthan, India. E-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jmh.JMH_46_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459072PMC

Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease.

Gynecol Oncol 2019 Apr 16. Epub 2019 Apr 16.

Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, United States of America.

Objective: Treatment planning requires accurate estimation of surgical complexity (SC) and residual disease (RD) at primary debulking surgery (PDS) for advanced ovarian cancer (OC). We sought to independently validate two published computed tomography (CT) prediction models.

Methods: We included stage IIIC/IV OC patients who underwent PDS from 2003 to 2011. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.04.011DOI Listing

A truncating MEIOB mutation responsible for familial primary ovarian insufficiency abolishes its interaction with its partner SPATA22 and their recruitment to DNA double-strand breaks.

EBioMedicine 2019 Apr 15. Epub 2019 Apr 15.

Institut Jacques Monod, Université Paris Diderot, CNRS UMR7592, Paris 75013, France; Université Paris Diderot-Paris 7, 75205 Paris Cedex 13, France. Electronic address:

Background: Primary Ovarian Insufficiency (POI), a major cause of infertility, affects about 1-3% of women under forty years of age. Although there is a growing list of causal genetic alterations, POI remains mostly idiopathic.

Methods: We performed exome sequencing (WES) of two sisters affected with POI, one unaffected sister and their mother from a consanguineous family. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2019.03.075DOI Listing

Overexpression of FER1L4 promotes the apoptosis and suppresses epithelial-mesenchymal transition and stemness markers via activating PI3K/AKT signaling pathway in osteosarcoma cells.

Pathol Res Pract 2019 Apr 6. Epub 2019 Apr 6.

Department of Orthopaedics, Beijing Friendship Hospital, Capital Medical University, 100050, PR China.

Novel long non-coding RNA Fer-1-like protein 4 (FER1L4) has been identified as a tumor suppressor in endometrial carcinoma, ovarian cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma. However, the function of FER1L4 in osteosarcoma has not been clear. The aim of the research was to explore the effects of FER1L4 in osteosarcoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2019.04.004DOI Listing

Metabolic and signalling network maps integration: application to cross-talk studies and omics data analysis in cancer.

BMC Bioinformatics 2019 Apr 18;20(Suppl 4):140. Epub 2019 Apr 18.

Institut Curie, 26 rue d'Ulm, F-75005, Paris, France.

Background: The interplay between metabolic processes and signalling pathways remains poorly understood. Global, detailed and comprehensive reconstructions of human metabolism and signalling pathways exist in the form of molecular maps, but they have never been integrated together. We aim at filling in this gap by integrating of both signalling and metabolic pathways allowing a visual exploration of multi-level omics data and study of cross-regulatory circuits between these processes in health and in disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12859-019-2682-zDOI Listing
April 2019
2 Reads

Comparison of urine, self-collected vaginal swab, and cervical swab samples for detecting human papillomavirus (HPV) with Roche Cobas HPV, Anyplex II HPV, and RealTime HR-S HPV assay.

J Virol Methods 2019 Apr 15;269:77-82. Epub 2019 Apr 15.

Department of Obstetrics and Gynecology, Korea University Guro Hospital, College of Medicine, Korea University, Seoul, Republic of Korea. Electronic address:

Background: Human papillomavirus (HPV) is well established as the main cause of cervical cancer. Non-invasive self-collected urine and vaginal sampling have the potential advantage of increasing patient compliance with cervical cancer screening.

Methods: Self-collected vaginal and urine samples and clinician-collected cervical samples were collected from 101 patients, including 84 patients with high grade squamous intraepithelial lesion and 17 patients with benign ovarian disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jviromet.2019.04.012DOI Listing
April 2019
1 Read

Frequency of hematologic and solid malignancies in the family history of 50 patients with acute myeloid leukemia - a single center analysis.

PLoS One 2019 18;14(4):e0215453. Epub 2019 Apr 18.

Department of Medicine III, University Hospital Munich, Ludwig-Maximilians-University Munich-Campus Großhadern, Munich, Germany.

Background And Objective: The revised World Health Organization classification of 2016 for myeloid neoplasms and acute leukemia added a section of myeloid neoplasms with germline predisposition. The main objective of our study was to evaluate the frequency of hematologic and solid malignancies in the family history of patients with acute myeloid leukemia (AML) by using a systemic pedigree interview. The family history was taken of 50 patients between 24 and 80 years. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0215453PLOS
April 2019
1 Read

Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer.

Anticancer Drugs 2019 Apr 16. Epub 2019 Apr 16.

Institute of Life Sciences.

Ovarian cancer is a heterogeneous disease with complex molecular and genetic hallmarks. Benefitting from profound understanding of molecular mechanisms in ovarian cancer pathogenesis, novel targeted drugs have been actively explored in preclinical studies and clinical trials. Considered as one of the most potent and effective targeted therapies for the treatment of ovarian cancer, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) take advantages of synthetic lethality mechanisms to prevent DNA damage repair in cancer cells and cause their death, especially in cancers with BRCA mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000793DOI Listing

Reproductive outcomes following treatment for a gynecological cancer diagnosis: a systematic review.

J Cancer Surviv 2019 Apr 17. Epub 2019 Apr 17.

Kids Cancer Centre, Sydney Children's Hospital, Sydney, NSW, 2031, Australia.

Purpose: Fertility treatments are available for women diagnosed with a gynecological malignancy, which is important for women who desire a biological family subsequent to treatment. The objective of this study was to report reproductive outcomes following fertility-sparing treatment for a gynaecological cancer.

Methods: Electronic databases were searched to identify studies that reported on reproductive outcomes after treatment for a gynecological malignancy. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11764-019-00749-x
Publisher Site
http://dx.doi.org/10.1007/s11764-019-00749-xDOI Listing
April 2019
2 Reads

Pancreaticobiliary metastasis presenting as primary mucinous ovarian neoplasm: A systematic literature review.

Gynecol Oncol Rep 2019 May 27;28:109-115. Epub 2019 Mar 27.

Temple University Hospital, Department of Obstetrics, Gynecology, and Reproductive Sciences, 3401 North Broad Street, Philadelphia, PA 19140, United States of America.

True primary mucinous ovarian carcinomas are rarer than originally thought and their clinical behavior and treatment response are different than more common epithelial ovarian carcinomas. Secondary ovarian neoplasms often mimic the clinical and histological features of mucinous ovarian cancer making their diagnosis, and therefore treatment, more difficult. Misdiagnosis can have a significant impact on both treatment and prognosis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23525789193003
Publisher Site
http://dx.doi.org/10.1016/j.gore.2019.03.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453658PMC
May 2019
1 Read

Epithelioid glioblastoma presenting as aphasia in a young adult with ovarian cancer: A case report.

Clin Case Rep 2019 Apr 18;7(4):821-825. Epub 2019 Mar 18.

Department of Neurosurgery Cooper University Hospital Camden New Jersey.

Our patient's clinical history and preoperative radiographic evaluation suggested central nervous system (CNS) metastatic disease. Ultimately, final pathology revealed epithelioid glioblastoma (eGBM), a newly classified CNS primary tumor. This reinforces the importance of direct tissue sampling and including eGBM on the differential for young patients with histories of systemic cancer presenting with new CNS lesions. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ccr3.2088
Publisher Site
http://dx.doi.org/10.1002/ccr3.2088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452522PMC
April 2019
2 Reads

Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer.

ACS Med Chem Lett 2019 Apr 7;10(4):656-660. Epub 2019 Feb 7.

Laboratory of Metals in Medicine (MetMed), Department of Chemistry "U. Schiff", University of Florence, via della Lastruccia 3, 50019 Sesto Fiorentino, Italy.

In recent years, a few successful attempts were made to repurpose the clinically approved antiarthritic gold drug, Auranofin (), as an anticancer agent. The present study shows that the iodido(triethylphosphine)gold(I) complex, ( hereafter)-an analogue where the thiosugar ligand is simply replaced by one iodide ligand-manifests a solution chemistry resembling that of and exerts similar cytotoxic and proapoptotic effects on A2780 human ovarian cancer cells . However, when evaluated in a preclinical orthotopic model of ovarian cancer, produces a far superior anticancer action than inducing a nearly complete tumor remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.9b00007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466815PMC

Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515.

ACS Med Chem Lett 2019 Apr 13;10(4):534-538. Epub 2019 Mar 13.

Oncology, Nerviano Medical Sciences S.r.l., Viale Pasteur 10, 20014 Nerviano, Milan, Italy.

Poly(ADP-ribose) polymerase-1 (PARP-1) is an enzyme involved in signaling and repair of DNA single strand breaks. PARP-1 employs NAD to modify substrate proteins via the attachment of poly(ADP-ribose) chains. PARP-1 is a well established target in oncology, as testified by the number of marketed drugs (e. Read More

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/acsmedchemlett.8b00569
Publisher Site
http://dx.doi.org/10.1021/acsmedchemlett.8b00569DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466814PMC
April 2019
2 Reads

Stimulative role of ST6GALNAC1 in proliferation, migration and invasion of ovarian cancer stem cells via the Akt signaling pathway.

Cancer Cell Int 2019 5;19:86. Epub 2019 Apr 5.

1Department of Obstetrics and Gynecology, The Second Hospital of Anhui Medical University, Hefei, 230601 People's Republic of China.

Background: Ovarian cancer is known as one of the most common cancers in the world among women. ST6GALNAC1 is highly expressed in cancer stem cells (CSCs), which correlates to high tumor-initiating, self-renewal and differentiation abilities. This present study aims to investigate how ST6GALNAC1 affects ovarian cancer stem cells (OCSCs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-019-0780-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451308PMC

Random-start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer.

Reprod Med Biol 2019 Apr 2;18(2):167-172. Epub 2019 Jan 2.

Comprehensive Reproductive Medicine, Graduate School Tokyo Medical and Dental University (TMDU) Tokyo Japan.

Purpose: Fertility preservation is an important issue for young cancer patients. Random-start controlled ovarian stimulation and double ovarian stimulation have been proposed for efficient oocyte retrieval within the limited time before cancer therapy. We aimed to clarify the efficacy of these new protocols within the Japanese population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/rmb2.12263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452013PMC
April 2019
1 Read

DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity.

JCI Insight 2019 Apr 18;4(8). Epub 2019 Apr 18.

Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, USA.

Specific antibody therapy, including mAbs and bispecific T cell engagers (BiTEs), are important new tools for cancer immunotherapy. However, these approaches are slow to develop and may be limited in their production, thus restricting the patients who can access these treatments. BiTEs exhibit a particularly short half-life and difficult production. Read More

View Article

Download full-text PDF

Source
https://insight.jci.org/articles/view/126086
Publisher Site
http://dx.doi.org/10.1172/jci.insight.126086DOI Listing
April 2019
2 Reads